Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PAULIEN
2024-516581-11-00Phase 3Completed
- Sponsor
- Amsterdam University Medical Center
- Start
- Nov 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of pembrolizumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoints: Objective response rate (ORR) at week 6 and Disease control rate (DCR) at week 6. Started Nov 2024; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-516581-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516581-11-00.